IL12A Antibody is a monoclonal antibody that binds exclusively to the p35 subunit of IL-12, which forms a heterodimer with the p40 subunit (encoded by the IL12B gene) to constitute the biologically active IL-12 cytokine . The antibody is engineered to recognize epitopes on the IL12A protein, enabling its detection in assays such as Western blot, ELISA, and immunoprecipitation .
Specificity: Targets the 35-kDa alpha chain of IL-12, distinguishing it from other IL-12 family members (e.g., IL-23, IL-27) .
Cross-reactivity: Limited to human IL12A, with no reported reactivity to murine or other species .
IL12A is critical for immune system regulation, particularly in:
Th1 Cell Differentiation: Drives naive T cells toward Th1 lineage, enhancing cell-mediated immunity .
NK Cell Activation: Stimulates interferon-gamma (IFN-γ) production and cytotoxic activity in natural killer (NK) cells .
Anti-Angiogenic Effects: Indirectly inhibits tumor angiogenesis via induction of IP-10/CXCL10 .
The IL12A Antibody is a versatile tool in immunology and oncology research:
Cross-reactivity: Requires validation to ensure specificity for IL12A versus IL-35 (formed with EBI3) .
Regulatory Status: For research use only; not approved for clinical diagnostics .
Toxicity in Therapeutics: While IL12A-based therapies show promise, systemic administration risks cytokine release syndrome (CRS), necessitating localized delivery .
Emerging studies focus on:
Cancer Immunotherapy: Engineering tumor-targeted IL12A antibodies to enhance anti-tumor immunity while minimizing toxicity .
Autoimmune Diseases: Investigating IL12A’s role in conditions like psoriasis, where IL12/IL23 inhibitors are already in use .
References Wikipedia: Interleukin 12. Thermo Fisher Scientific: IL12A Monoclonal Antibody (OTI2A8). Cusabio: IL12A Antibodies and Related Products. PMC: IL12 Immune Therapy Clinical Trial Review. GeneCards: IL12A Gene.